SCHEMBL4967916

SCHEMBL4967916

COc1cc2ncnc(N3CCC(NC(=O)Nc4ccc(N5CCCCC5)cc4)C3)c2cc1OC

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 5/20 0.57
KIT P10721 3/20 0.57
KDR P35968 1/20 0.57
HTR1A P08908 3/20 0.54
ENPP1 P22413 2/20 0.53
HTR7 P34969 2/20 0.52
ADRA1D P25100 1/20 0.52
ADRA1A P35348 1/20 0.52
ADRA1B P35368 1/20 0.52
PDE10A Q9Y233 1/20 0.52
ACHE P22303 4/20 0.52
BACE1 P56817 4/20 0.52
PDGFRB P09619 8/20 0.51
PDE3A Q14432 1/20 0.51
FLT3 P36888 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4966363 0.99 PDGFRA (0.56) PDGFRAKITKDRHTR1AENPP1
SCHEMBL4969629 0.94 PDGFRA (0.60) PDGFRAKITKDRENPP1ACHE
SCHEMBL4965465 0.92 PDE10A (0.57) PDGFRAKITKDRHTR1AENPP1
SCHEMBL4966727 0.89 PDGFRA (0.59) PDGFRAKITKDRENPP1PDGFRB
SCHEMBL4967719 0.89 PDGFRB (0.65) PDGFRAKITKDRHTR1AENPP1
SCHEMBL4967131 0.88 PDGFRA (0.51) PDGFRAKITKDRHTR1AENPP1
SCHEMBL4965795 0.87 PDGFRB (0.66) PDGFRAKITKDRENPP1PDE10A
SCHEMBL4966797 0.87 PDE10A (0.56) PDGFRAKITKDRENPP1PDE10A
SCHEMBL4969305 0.87 PDE10A (0.61) PDGFRAKITKDRENPP1PDE10A
SCHEMBL4965715 0.86 PDGFRA (0.60) PDGFRAKITKDRPDE10APDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899319-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP disclosed
EP-1893206-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-05 EP disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
WO-2006135649-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135636-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, CDC42BPG, PRKCQ PDGFRA 460/4885KIT 197/4885KDR 483/4885
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, BMX, ABL1 PDGFRA 74/4885KIT 104/4885KDR 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.